Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation

Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice

The efficacy and safety of a novel oral Xa inhibitor for stroke and systemic embolism, namely rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in Japanese clinical practice.

Inclusion Criteria:

Patients who meet all the criteria below

• Patients aged over 20 years
• Patients diagnosed with non-valvular atrial fibrillation
• Patients who are treated or will be treated with rivaroxaban
• Patients from whom written informed consent has been obtained

Exclusion Criteria:

Patients who meet any of the criteria below

• The following patients in whom rivaroxaban is contraindicated for use
• Patients with a history of allergies to the ingredients contained in this drug
• Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events)
• Patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh classification)
• Patients having renal failure (creatinine clearance: <15 mL/min)
• Women who are or are likely to be pregnant
• Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir and indinavir)
• Patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))